Literature DB >> 29209563

Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab.

Alexandre Reuben1, Mariana Petaccia de Macedo2, Jennifer McQuade3, Aron Joon4, Zhiyong Ren5, Tiffany Calderone2, Brandy Conner2, Khalida Wani2, Zachary A Cooper1,6, Hussein Tawbi3, Michael T Tetzlaff2,5, Robert F Padera7, Jean-Bernard Durand8, Alexander J Lazar2,5, Jennifer A Wargo1,6, Michael A Davies2,3,9.   

Abstract

Autoimmune myocarditis is a rare but often fatal toxicity of checkpoint inhibitor immunotherapy. To improve the understanding of this complication, we performed immune profiling on post-mortem tissue from a patient with metastatic melanoma who had steroid-responsive hepatitis, steroid-refractory myocarditis, and shrinking lung metastases after ipilimumab treatment. Histological analysis of heart tissue demonstrated findings consistent with giant cell myocarditis (GCM). The immune infiltrate in the heart was largely comprised of CD4+ T cells, whereas the liver had very few T cells, and CD8+ T cells were predominant in the responding lung metastases. TCR sequencing identified high T cell clonality in the lung metastases. The TCR repertoire showed low clonality in the heart and minimal overlap with the liver (1.2%), but some overlap with lung metastases (9.9%). Transcriptional profiling identified several potential mediators of increased inflammation in the heart. These findings provide new insights into the pathogenesis of autoimmune myocarditis with ipilimumab.

Entities:  

Keywords:  Ipilimumab; Melanoma; Myocarditis

Year:  2017        PMID: 29209563      PMCID: PMC5706622          DOI: 10.1080/2162402X.2017.1361097

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  21 in total

1.  The expression and possible roles of chemokine CXCL11 and its receptor CXCR3 in the human endometrium.

Authors:  Yasushi Hirota; Yutaka Osuga; Kaori Koga; Osamu Yoshino; Tetsuya Hirata; Chieko Morimoto; Miyuki Harada; Yuri Takemura; Emi Nose; Tetsu Yano; Osamu Tsutsumi; Yuji Taketani
Journal:  J Immunol       Date:  2006-12-15       Impact factor: 5.422

2.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

Authors:  Dirk Schadendorf; F Stephen Hodi; Caroline Robert; Jeffrey S Weber; Kim Margolin; Omid Hamid; Debra Patt; Tai-Tsang Chen; David M Berman; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

Review 3.  Giant Cell Myocarditis: A Brief Review.

Authors:  Jin Xu; Erin G Brooks
Journal:  Arch Pathol Lab Med       Date:  2016-12       Impact factor: 5.534

4.  Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators.

Authors:  L T Cooper; G J Berry; R Shabetai
Journal:  N Engl J Med       Date:  1997-06-26       Impact factor: 91.245

5.  Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression.

Authors:  Riina Kandolin; Jukka Lehtonen; Kaisa Salmenkivi; Anne Räisänen-Sokolowski; Jyri Lommi; Markku Kupari
Journal:  Circ Heart Fail       Date:  2012-11-13       Impact factor: 8.790

6.  Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

Authors:  Pei-Ling Chen; Whijae Roh; Alexandre Reuben; Zachary A Cooper; Christine N Spencer; Peter A Prieto; John P Miller; Roland L Bassett; Vancheswaran Gopalakrishnan; Khalida Wani; Mariana Petaccia De Macedo; Jacob L Austin-Breneman; Hong Jiang; Qing Chang; Sangeetha M Reddy; Wei-Shen Chen; Michael T Tetzlaff; Russell J Broaddus; Michael A Davies; Jeffrey E Gershenwald; Lauren Haydu; Alexander J Lazar; Sapna P Patel; Patrick Hwu; Wen-Jen Hwu; Adi Diab; Isabella C Glitza; Scott E Woodman; Luis M Vence; Ignacio I Wistuba; Rodabe N Amaria; Lawrence N Kwong; Victor Prieto; R Eric Davis; Wencai Ma; Willem W Overwijk; Arlene H Sharpe; Jianhua Hu; P Andrew Futreal; Jorge Blando; Padmanee Sharma; James P Allison; Lynda Chin; Jennifer A Wargo
Journal:  Cancer Discov       Date:  2016-06-14       Impact factor: 39.397

7.  Autoimmune Cardiotoxicity of Cancer Immunotherapy.

Authors:  Feixiong Cheng; Joseph Loscalzo
Journal:  Trends Immunol       Date:  2016-12-02       Impact factor: 16.687

8.  Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.

Authors:  Lucie Heinzerling; Patrick A Ott; F Stephen Hodi; Aliya N Husain; Azadeh Tajmir-Riahi; Hussein Tawbi; Matthias Pauschinger; Thomas F Gajewski; Evan J Lipson; Jason J Luke
Journal:  J Immunother Cancer       Date:  2016-08-16       Impact factor: 13.751

9.  Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study.

Authors:  Viktor H Koelzer; Sacha I Rothschild; Deborah Zihler; Andreas Wicki; Berenika Willi; Niels Willi; Michèle Voegeli; Gieri Cathomas; Alfred Zippelius; Kirsten D Mertz
Journal:  J Immunother Cancer       Date:  2016-03-15       Impact factor: 13.751

10.  Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

Authors:  Alexandre Reuben; Christine N Spencer; Peter A Prieto; Vancheswaran Gopalakrishnan; Sangeetha M Reddy; John P Miller; Xizeng Mao; Mariana Petaccia De Macedo; Jiong Chen; Xingzhi Song; Hong Jiang; Pei-Ling Chen; Hannah C Beird; Haven R Garber; Whijae Roh; Khalida Wani; Eveline Chen; Cara Haymaker; Marie-Andrée Forget; Latasha D Little; Curtis Gumbs; Rebecca L Thornton; Courtney W Hudgens; Wei-Shen Chen; Jacob Austin-Breneman; Robert Szczepaniak Sloane; Luigi Nezi; Alexandria P Cogdill; Chantale Bernatchez; Jason Roszik; Patrick Hwu; Scott E Woodman; Lynda Chin; Hussein Tawbi; Michael A Davies; Jeffrey E Gershenwald; Rodabe N Amaria; Isabella C Glitza; Adi Diab; Sapna P Patel; Jianhua Hu; Jeffrey E Lee; Elizabeth A Grimm; Michael T Tetzlaff; Alexander J Lazar; Ignacio I Wistuba; Karen Clise-Dwyer; Brett W Carter; Jianhua Zhang; P Andrew Futreal; Padmanee Sharma; James P Allison; Zachary A Cooper; Jennifer A Wargo
Journal:  NPJ Genom Med       Date:  2017-04-07       Impact factor: 8.617

View more
  17 in total

1.  Immune Checkpoint Inhibitor-Associated Myocarditis.

Authors:  Sarju Ganatra; Tomas G Neilan
Journal:  Oncologist       Date:  2018-05-25

Review 2.  T cell checkpoint regulators in the heart.

Authors:  Nir Grabie; Andrew H Lichtman; Robert Padera
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

3.  Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis.

Authors:  Xue Chen; Aimin Jiang; Rui Zhang; Xiao Fu; Na Liu; Chuchu Shi; Jingjing Wang; Xiaoqiang Zheng; Tao Tian; Xuan Liang; Zhiping Ruan; Yu Yao
Journal:  Front Cardiovasc Med       Date:  2022-05-20

Review 4.  Heart failure in cancer: role of checkpoint inhibitors.

Authors:  Murilo Delgobo; Stefan Frantz
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

5.  Alemtuzumab and Fatal Myocarditis.

Authors:  Neil J Scolding; Hiam Ali; Mary Sheppard; Andre R Simon
Journal:  Neurol Clin Pract       Date:  2021-02

6.  Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action.

Authors:  Tomas G Neilan; Mace L Rothenberg; Laleh Amiri-Kordestani; Ryan J Sullivan; Richard M Steingart; William Gregory; Subramanian Hariharan; Tarek A Hammad; JoAnn Lindenfeld; Martin J Murphy; Javid J Moslehi
Journal:  Oncologist       Date:  2018-05-25

Review 7.  Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.

Authors:  Alan H Baik; Katy K Tsai; David Y Oh; Mandar A Aras
Journal:  Clin Sci (Lond)       Date:  2021-03-12       Impact factor: 6.124

Review 8.  Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects.

Authors:  Wenlu Zou; Jie Lu; Yan Hao
Journal:  J Inflamm Res       Date:  2021-07-08

9.  Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis.

Authors:  Igor Puzanov; Poornima Subramanian; Yan V Yatsynovich; David M Jacobs; Maya R Chilbert; Umesh C Sharma; Fumito Ito; Steven G Feuerstein; Filip Stefanovic; Benjamin Switzer; Mark D Hicar; Anne B Curtis; Edward J Spangenthal; Grace K Dy; Marc S Ernstoff; Pankit Vachhani; Brian J Page; Nikhil Agrawal; Arjun Khunger; Ankita Kapoor; Alexander Hattoum; Jerome J Schentag
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 12.469

Review 10.  Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases.

Authors:  Emma Matzen; Lars Erik Bartels; Brian Løgstrup; Stine Horskær; Christina Stilling; Frede Donskov
Journal:  Cardiooncology       Date:  2021-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.